Earnings per share growth for the full year is projected to be 13%-15%. "The Pink Sheet" (May 1, p. 23) incorrectly referred to a projected revenue growth rate. In addition, the projection that Zocor sales will top $3 bil. in the U.S. is an extrapolation by "The Pink Sheet" based on the first quarter performance of the drug
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth